Abstract 1619: A prognostic score for advanced non-small cell lung cancer with PD-1/L1 inhibitors

Abstract

Abstract Background: Programmed death 1 (PD-1)/programmed death-legend 1(PD-L1) inhibitors have shown clinical benefits for a proportion of advanced lung cancer patients. This study aimed to develop a prognostic store with routinely available variables to identify non-small cell lung cancer (NSCLC) patients who likely benefit from PD-1/L1 inhibitors. Methods: 412 patients who received PD-1/L1 inhibitors were retrospectively collected from Massachusetts General Hospital (MGH) and Brigham and Women's Hospital (BWH) between Nov 2013 and Jan 2018. Demographic, clinical, and common laboratory tests were collected. Penalized Cox proportional hazard model with group minimax concave penalty (MCP) penalty was applied for variable section and coefficient estimation. Model performance was assessed by calculating area under the receiver operating curves (AUC). A prognostic score was developed to categorize advanced NSCLC patients into good, intermediate and poor groups. Results: Median PFS was 3.6 (95% CI: 2.9 - 4.3) months, median OS was 18.4 (95% CI: 14.2-24.9) months. A prognostic scoring model incorporating the weighted coefficients of PD-L1 expression level, EGFR mutation status, ECOG performance status, and albumin level was developed. Median PFS were 1.7 (95% CI: 1.5-2.1) vs 3.2 (95% CI: 2.7-6.3) vs 6.2 (95% CI: 4.9-9.7) months for the poor, intermediate and good groups, respectively. Median OS were 8.2 (95% CI: 4.5-14.1) vs 14.9 (95% CI: 11.8-30.0) vs 34.7 (95% CI: 26.2 -NE) months for the poor, intermediate and good groups, respectively. Conclusions: a prognostic score combining PD-L1 expression level, EGFR mutation status, ECOG performance status, and albumin level may help to identify advanced NSCLC patients who likely benefit from PD-1/L1 inhibitors. Citation Format: Qianyu Yuan, Mulong Du, David Christiani. A prognostic score for advanced non-small cell lung cancer with PD-1/L1 inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1619.